SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp move is drawing attention after Morgan Stanley named it a top pick, citing accelerating AWS growth and AI opportunities; traders are also pointing to Amazons Trainium software announcement as a potential boost to cloud-chip adoption. The reaction is broadly bullish, though some remain cautious about heavy AI capital spending and whether the gains will hold.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Reports of Lundbecks interest in acquiring Xeris have fueled heavy-volume trading and takeover speculation, though the company has said it is not for sale and no deal is confirmed. Traders are split between expecting further buyer interest and viewing the chatter as unsubstantiated, while some point to Recorlev growth and XP-8121s pipeline potential as standalone reasons for optimism.

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of treatments for hematologic diseases. It assembles a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. The company was founded in October 2017 and is headquartered in Watertown, MA.

Disc Medicine Inc

Disc Medicine shares surged after bitopertin met all primary and secondary endpoints in the Phase 3 APOLLO trial for erythropoietic protoporphyria, supporting a planned FDA resubmission. Traders are debating whether the move can continue, with some citing short-squeeze potential and others warning of profit-taking, safety concerns around dizziness, and the fact that FDA approval is still pending.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Recent open-market purchases by Celsius executives and directors have fueled bullish discussion around the shares, while skeptics question whether the buys signal durable confidence given concerns about the core brands sales and management execution. Traders also revive speculation about a Pepsi buyout, but no deal is confirmed.

Vicor Corp. engages in the design, development, manufacture, and marketing of modular power components. The firm provides complete power systems based upon a portfolio of patented technologies. Its products include AC-DC converters, power systems, and accessories. The company was founded by Patrizio Vinciarelli in 1981 and is headquartered in Andover, MA.

Vicor Corp.

Anticipation of Vicors Q3 earnings is driving discussion after the company raised its sequential growth outlook twice, with traders pointing to higher royalties from its Vertical Power Delivery licensing. Bulls expect the stronger outlook to show up in results, while others are wary of the sharp pullback and volatility despite the guidance increases.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix shares are under pressure as EyePoints failed wet-AMD trial has heightened doubts about TKI-based treatments, prompting traders to question whether those concerns could extend to Oculars AXPAXLI program. Some investors view the selloff as spillover from a competitors results, while others cite clinical uncertainty and the departure of Oculars chief strategy officer as additional concerns.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

The FDA-cleared expansion of Alpha Taus REGAIN trial in recurrent glioblastoma is a key focus, alongside planned trial data at SNO 2026. Traders are optimistic about early local-control results, while some note that they come from a small initial cohort; the completed enrollment of the pancreatic IMPACT study is another pipeline catalyst discussed.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

A stronger-than-guided Q3 report and an upbeat 2027 EBITDA outlook are driving CLFs rally. Bulls see improving steel prices and earnings potential, while skeptics warn that debt and the reliance on favorable price forecasts could limit the recovery; traders are also debating whether the move will hold or fade as a sell-the-news rally.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO decline dominates discussion, with traders pointing to insider selling and upcoming share unlocks alongside concerns about valuation, scaling and reliance on OpenAI amid weakness across AI stocks. Some see the selloff as an oversold buying opportunity and are averaging in, while others expect further downside.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ rebounded as technology and AI stocks recovered from a sharp selloff, with traders debating whether the move marks a durable recovery or a low-volume bull trap. Upcoming megacap earnings and AI spending plans are a key focus for the tech-heavy index.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

STRO Stock Plummets 15% —  What Drove The Selloff?

Equity

H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004 by the company. 


Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma stock falls after its STRO-004 Phase 1 update, with DLTs reported at the highest dose and the next update planned for 2027.read more...

Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates

Upstream Bio, Inc. (UPB) delivered earnings and revenue surprises of +6.41% and +15.37%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates

BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Gemini Space Posts Upbeat Q1 Results, Joins Figma, Sutro Biopharma And Other Big Stocks Moving Higher On Friday

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after strong financial results and $100M investment.read more...

MannKind (MNKD) Reports Q1 Loss, Misses Revenue Estimates

MannKind (MNKD) delivered earnings and revenue surprises of -150.00% and -13.05%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma (NASDAQ:STRO) Stock Rating Upgraded by Truist Financial

Truist Financial raised shares of Sutro Biopharma to a "strong-buy" rating in a research report on Monday...

Sutro Biopharma (NASDAQ:STRO) Sets New 1-Year High  - Still a Buy?

Sutro Biopharma (NASDAQ:STRO) Sets New 52-Week High - Still a Buy...

Ocugen (OCGN) Reports Q1 Loss, Beats Revenue Estimates

Ocugen (OCGN) delivered earnings and revenue surprises of -12.57% and +27.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma (NASDAQ:STRO) Upgraded by Mizuho to "Strong-Buy" Rating

Mizuho upgraded shares of Sutro Biopharma to a "strong-buy" rating in a report on Thursday...

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Sutro Biopharma Inc

Bullish Sentiment

<ul class="summary-bullets"><li>In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers.</li><li>A fuller update is planned for the first half of 2027.</li><li>As of June 30, Sutro held $164.3 million in cash and securities, enough to fund operations into at least the second quarter of 2028.</li></ul><p>Shares of Sutro Biopharma (STRO) fell 15% on Wednesday after the company reported second-quarter results and an early look at its lead experimental cancer drug STRO-004.</p><p>H.C. Wainwright believes the selloff largely reflects an overreaction to the limited efficacy details disclosed for STRO-004. The firm said investors had hoped for a more complete readout or enough patient-level information to judge the strength and staying power of the responses. Wainwright views the reaction as overdone because the data remain early, while the drug already shows clearer safety advantages over approved tissue-factor antibody-drug conjugates. The firm reiterated its ‘Buy’ rating and $50 price target. The price target implies a potential upside of 135% from the stock's closing price on Wednesday.&nbsp;</p><h2 class="st-heading-2">Early Signs Of Activity With Good Tolerability</h2><p>In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers. The drug was generally well tolerated, with dose-limiting side effects appearing only at the highest dose tested and leading to reductions rather than dropouts, the company said.</p><p>The overall rate of patients stopping treatment because of side effects was low at 6%. Enrollment of the first dose groups moved faster than expected, and the company is still refining the best dose.</p><p>A fuller update is planned for the first half of 2027. CEO Jane Chung said the early STRO-004 findings strengthen confidence in the drug’s potential to deliver meaningful benefit and open the door to combinations.</p><h2 class="st-heading-2">Pipeline Progress And Solid Cash Position</h2><p>Beyond STRO-004, Sutro expects to start clinical testing of STRO-006, another antibody-drug conjugate for solid tumors, in the third quarter of 2026. Its wholly owned STRO-227 program remains on track for an investigational new drug application later this year and offers a longer-term growth path for the company’s platform.</p><p>As of June 30, Sutro held $164.3 million in cash and securities, enough to fund operations into at least the second quarter of 2028. Second-quarter revenue was $9.8 million, mainly from its collaboration with Japan's Astellas Pharma, while the net loss was $38.5 million.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around STRO stock rose from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume remained at ‘high’ levels.</p><p>A Stocktwits user expressed optimism about the company’s pipeline.</p><p><stembedurl>https://www.stocktwits.com/KY3000/message/661632677</stembedurl></p><p><a href="https://stocktwits.com/symbol/STRO">STRO stock</a> has gained 84% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-in-focus-as-candel-nears-year-end-bla-filing-for-prostate-cancer-drug-eyes-10-16-b-opportunity/cZo8g37RJWo">CADL Stock In Focus As Candel Nears Year-End BLA Filing For Prostate Cancer Drug — Eyes $10–$16B Opportunity</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Sutro Biopharma logo is seen displayed on the screen of a smart tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

In its early-stage trial of patients with advanced solid tumors who had already tried several prior treatments, Sutro saw tumor shrinkage in some cases of pancreatic, head and neck, and non-small cell lung cancers.A fuller update is planned for the first 

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$11.14
Prev Close	$10.94
Open	$11.06
Dividend Yield	0.00%
50-Day Moving Average	$17.95
Beta	1.50
Avg. Volume	318,291.81
PE Ratio	-0.63

52-Week High	$43.85
52-Week Low	$7.15
Market Capitalization	$181.4M
EPS (Annual)	-$22.49
Price to Book	-1.76
Revenue Per Employee	$748,058.39

Feed

News

Sentiment

Earnings

Fundamentals

Info

STRO Fundamentals